FLT3 Mutational Analysis
PCR
Indication
Detection of activating mutations in the receptor tyrosine kinase FLT3 that occur in 15% of acute myeloid leukemia. This data can provides independent prognostic information and may be used to select tumors that are appropriate for targeted therapy.
Methodology
Fluorescently-labeled primers are used to detect the ITD and D835 mutations; overnight restriction digestion is done on D835 PCR products. Capillary electrophoresis / GeneScan analysis is used to distinguish the wild type.
Test Parameters
This assay will detect internal tandem duplications (ITD) in the juxtamembrane domain and point mutations in codons 835 and 836. The sensitivity of the test is approximately one cell with mutated FLT3 in 20-100 total cells (1-5%).
Turnaround Time
Four to six working days
Sample Requirements
- 10 ml peripheral blood in purple top tube (EDTA Vacutainer), sent on wet ice
or - 2-5 ml of bone marrow aspirate, sent on wet ice
Note: This test is only available for patients seen by physicians at M. D. Anderson Cancer Center.
CPT Codes
83890 (DNA Isolation), 83900, 83892, 83909, 83912
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.